Olesya Kharenko
Olesya Kharenko
Research Scientist
Verified email at resverlogix.com
Title
Cited by
Cited by
Year
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist
KG McLure, EM Gesner, L Tsujikawa, OA Kharenko, S Attwell, ...
PloS one 8 (12), e83190, 2013
1542013
Metal-induced folding of a designed metalloprotein
OA Kharenko, MY Ogawa
Journal of inorganic biochemistry 98 (11), 1971-1974, 2004
652004
Cu(I) Luminescence from the Tetranuclear Cu4S4 Cofactor of a Synthetic 4-Helix Bundle
OA Kharenko, DC Kennedy, B Demeler, MJ Maroney, MY Ogawa
Journal of the American Chemical Society 127 (21), 7678-7679, 2005
542005
Incorporating electron-transfer functionality into synthetic metalloproteins from the bottom-up
J Hong, OA Kharenko, MY Ogawa
Inorganic chemistry 45 (25), 9974-9984, 2006
342006
RVX-297-a novel BD2 selective inhibitor of BET bromodomains
OA Kharenko, EM Gesner, RG Patel, K Norek, A White, E Fontano, ...
Biochemical and biophysical research communications 477 (1), 62-67, 2016
312016
Discovery of a new chemical series of BRD4 (1) inhibitors using protein-ligand docking and structure-guided design
BC Duffy, S Liu, GS Martin, R Wang, MM Hsia, H Zhao, C Guo, M Ellis, ...
Bioorganic & Medicinal Chemistry Letters 25 (14), 2818-2823, 2015
222015
Abscisic acid metabolism and lipid accumulation of a cell suspension culture of Lesquerella fendleri
OA Kharenko, LI Zaharia, M Giblin, V Čekić, DC Taylor, CD Palmer, ...
Plant Cell, Tissue and Organ Culture (PCTOC) 105 (3), 415-422, 2011
212011
Evidence that a miniature CuI metalloprotein undergoes collisional electron transfer in the inverted Marcus region
J Hong, OA Kharenko, J Fan, F Xie, AK Petros, BR Gibney, MY Ogawa
Angewandte Chemie International Edition 45 (37), 6137-6140, 2006
212006
Molecular mechanisms in the activation of abscisic acid receptor PYR1
L Dorosh, OA Kharenko, N Rajagopalan, MC Loewen, M Stepanova
PLoS Comput Biol 9 (6), e1003114, 2013
192013
Design and characterization of novel covalent bromodomain and extra-terminal domain (BET) inhibitors targeting a methionine
OA Kharenko, RG Patel, SD Brown, C Calosing, A White, ...
Journal of medicinal chemistry 61 (18), 8202-8211, 2018
182018
Identification and characterization of interactions between abscisic acid and mitochondrial adenine nucleotide translocators
OA Kharenko, J Boyd, KM Nelson, SR Abrams, MC Loewen
Biochemical Journal 437 (1), 117-123, 2011
172011
Electron-transfer functionality of synthetic coiled-coil metalloproteins
MY Ogawa, J Fan, A Fedorova, J Hong, OA Kharenko, AY Kornilova, ...
Journal of the Brazilian Chemical Society 17 (8), 1516-1521, 2006
122006
Identification and characterization of interactions between abscisic acid and human heat shock protein 70 family members
OA Kharenko, D Polichuk, KM Nelson, SR Abrams, MC Loewen
The Journal of Biochemistry 154 (4), 383-391, 2013
112013
Novel approaches to targeting BRD4
OA Kharenko, HC Hansen
Drug Discovery Today: Technologies 24, 19-24, 2017
102017
Abscisic acid binds to recombinant Arabidopsis thaliana G-protein coupled receptor-type G-protein 1 in Sacaromycese cerevisiae and in vitro
OA Kharenko, P Choudhary, MC Loewen
Plant physiology and biochemistry 68, 32-36, 2013
92013
Abstract C86: The clinical candidate ZEN-3694, a novel BET bromodomain inhibitor, is efficacious in the treatment of a variety of solid tumor and hematological malignancies …
S Attwell, E Campeau, R Jahagirdar, O Kharenko, K Norek, L Tsujikawa, ...
Molecular Cancer Therapeutics 14 (12 Supplement 2), C86-C86, 2015
42015
Preclinical characterization of ZEN-3694, a novel BET bromodomain inhibitor entering phase I studies for metastatic castration-resistant prostate cancer (mCRPC)
S Attwell, R Jahagirdar, K Norek, C Calosing, L Tsujikawa, OA Kharenko, ...
CANCER RESEARCH 76, 2016
32016
Abstract LB-207: Preclinical characterization of ZEN-3694, a novel BET bromodomain inhibitor entering phase I studies for metastatic castration-resistant prostate cancer (mCRPC)
S Attwell, R Jahagirdar, K Norek, C Calosing, L Tsujikawa, OA Kharenko, ...
Cancer research 76 (14 Supplement), LB-207-LB-207, 2016
22016
Abstract LB-92: RVX-2135 is a novel, orally bioavailable epigenetic BET inhibitor that synergizes with cytarabine and idarubicin to inhibit proliferation of acute myeloid …
E Campeau, R Jahagirdar, J Wu, EM Gesner, O Kharenko, R Yu, S Attwell, ...
Cancer Research 73 (8 Supplement), LB-92-LB-92, 2013
22013
Characterization of the ATP-translocating properties of the predicted Arabidopsis thaliana mitochondrial adenine nucleotide translocator 2
OA Kharenko, MC Loewen
Botany 88 (7), 685-690, 2010
22010
The system can't perform the operation now. Try again later.
Articles 1–20